1. Home
  2. SCM vs TNXP Comparison

SCM vs TNXP Comparison

Compare SCM & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$7.96

Market Cap

244.3M

Sector

Finance

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$10.85

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCM
TNXP
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.3M
199.7M
IPO Year
2012
2008

Fundamental Metrics

Financial Performance
Metric
SCM
TNXP
Price
$7.96
$10.85
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
148.9K
413.4K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
14.22%
N/A
EPS Growth
N/A
91.75
EPS
0.62
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
$0.33
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
$12.82
N/A
Revenue Growth
N/A
29.85
52 Week Low
$6.83
$9.40
52 Week High
$13.55
$25.69

Technical Indicators

Market Signals
Indicator
SCM
TNXP
Relative Strength Index (RSI) 39.40 33.24
Support Level $7.78 $10.03
Resistance Level $8.92 $12.99
Average True Range (ATR) 0.23 0.55
MACD -0.07 -0.28
Stochastic Oscillator 16.07 10.01

Price Performance

Historical Comparison
SCM
TNXP

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: